Home > Division of Cancer RNA Research
Division of Cancer RNA Research
- Jul. 31, 2025
- Nanami Yamano, a medical student from Hiroshima University who participated in a 4-month clinical training program, received the Excellence Award at the Research Presentation!
- Jul. 25, 2025
- Tomoya Muto's project has been accepted for JST FOREST!
- Jul. 22, 2025
- Our collaborative research with Dr. Takumi Kitamoto’s group at Chiba University has been published in Diabetes!
- Jul. 15, 2025
- Our collaborative research with Dr Kunimoto and colleagues at Yokohama City University has been published in HemaSphere!
- Jul. 8, 2025
- Mina Yoshida gave an oral talk at the RNA2025 in Sendai!
- Jul. 4, 2025
- Akihide Yoshimi gave an invited lecture at the 15AGW (15th International Workshop on Advanced Genomics) .
- Jul. 2, 2025
- Congrats to Hirotaka Matsui― his paper just came out in Scientific Reports.
- Jun. 27, 2025
- Congrats to Hirofumi Yamauchi ― his paper just came out in BioTechniques.
- Jun. 16, 2025
- Akihide Yoshimi gave an invited lecture at the 41st Annual Meeting of the Japan Society of Drug Delivery System.
- May 31, 2025
- Mina Yoshida presented a poster at the 30th Annual Meeting of the RNA Society in San Diego.

Our Research Interest
Our studies have been focused on how RNA processing including RNA splicing is altered in cancer and functionally drives cancer initiation and maintenance. The advent of high-throughput transcriptome sequencing has provided a wealth of information on RNA splicing on a genome-wide scale. It is now understood that > 95% of human genes are subject to alternative splicing. RNA splicing is considered to be a major mediator of proteome diversity through its ability to generate multiple transcripts with differing amino acid sequences from a single gene. The discovery of recurrent mutations in components of the RNA-splicing machinery in 2011 further highlighted the importance of aberrant splicing in cancer as well as a potential therapeutic vulnerability for cells bearing these mutations. Despite the major advances in our understanding of the genomics, molecular biology and therapeutic implications of altered RNA processing in cancer, the full contribution of aberrant RNA splicing to cancer pathogenesis has not been fully elucidated. Our aim is to contribute to the full understanding of the pathogenic roles of altered RNA processing in a variety of cancers and to the development of therapeutically efficacious and safe strategies to improve the outcome of cancer patients.

(Figure was made by using Wordle based on our recent papers)